PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19

Recruiting

Conditions: COVID-19

First Posted Date: 2023-06-06

Last Posted Date: 2025-06-05

Lead Sponsor: Pfizer

Target Recruit Count: 3000

Registration Number: NCT05890612

Locations: 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Phase 2

Completed

Conditions: Healthy Participants

Interventions: Biological: Combination [RSVpreF+BNTb162b2]
Biological: Bivalent BNT162b2 (original/Omi BA.4/BA.5)
Biological: RSVpreF
Biological: QIV
Biological: Normal Saline Placebo

First Posted Date: 2023-06-02

Last Posted Date: 2024-12-18

Lead Sponsor: Pfizer

Target Recruit Count: 1142

Registration Number: NCT05886777

Locations: 🇺🇸
DM Clinical Research, Martin Diagnostic Clinic, Tomball, Texas, United States
🇺🇸
West Coast Research, Dublin, California, United States
🇺🇸
Marvel Clinical Research, Huntington Beach, California, United States

and more 31 locations

A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: PF-07817883

First Posted Date: 2023-06-01

Last Posted Date: 2024-08-16

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT05884554

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
🇺🇸
Research Centers of America, Hollywood, Florida, United States

and more 3 locations

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Phase 2

Recruiting

Conditions: Lupus Erythematosus, Systemic
Lupus Erythematosus, Cutaneous

Interventions: Drug: PF-06823859
Drug: Placebo

First Posted Date: 2023-05-30

Last Posted Date: 2025-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT05879718

Locations: 🇨🇦
Alberta Dermasurgery Centre, Edmonton, Alberta, Canada
🇺🇸
Perlman Clinic, La Jolla, California, United States
🇺🇸
UCSD - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California, United States

and more 33 locations

Study of GBT021601 in Participants With Renal Impairment

Phase 1

Terminated

Conditions: Renal Impairment

Interventions: Drug: GBT021601

First Posted Date: 2023-05-26

Last Posted Date: 2024-10-15

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT05878704

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸
Nucleus Network, Saint Paul, Minnesota, United States

A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: placebo
Drug: moxifloxacin
Drug: sisunatovir

First Posted Date: 2023-05-26

Last Posted Date: 2024-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT05878522

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

Active, not recruiting

Conditions: SARS-CoV-2
COVID-19
Post-Acute COVID-19 Syndrome

Interventions: Biological: Pfizer-BioNTech COVID-19 mRNA vaccine

First Posted Date: 2023-05-25

Last Posted Date: 2025-05-22

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05876377

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 20-valent pneumococcal conjugate vaccine

First Posted Date: 2023-05-25

Last Posted Date: 2024-10-24

Lead Sponsor: Pfizer

Target Recruit Count: 405

Registration Number: NCT05875727

Locations: 🇮🇳
Jawahar Lal Nehru Hospital, Ajmer, Rajasthan, India
🇮🇳
Jawahar Lal Nehru Medical College, Ajmer, Rajasthan, India
🇮🇳
Nirmal Hospital Pvt Ltd., Surat, Gujarat, India

and more 4 locations

A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: 200 mg RV521/78 µCi [ 14C]-RV521.

First Posted Date: 2023-05-24

Last Posted Date: 2024-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT05873764

Locations: 🇺🇸
Pharmaron Clinical Pharmacology Center, Baltimore, Maryland, United States

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

Completed

Conditions: Gonorrhea
Chlamydia
Meningococcal Vaccines

Interventions: Biological: Trumenba Vaccine
Biological: MenACWY Vaccine

First Posted Date: 2023-05-24

Last Posted Date: 2025-04-17

Lead Sponsor: Pfizer

Target Recruit Count: 999

Registration Number: NCT05873751

Locations: 🇺🇸
Pfizer, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy